Wechselwirkungen von Epoprostenol

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

…fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8 , 5.9) ] • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see Warnings and Precautions (5.8 , 5.10) ] • Pregnancy ( 4 ) (Fachinformation zu Diclofenac und Misoprostol, Gegenanzeigen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. (Fachinformation zu Ketorolac, Gegenanzeigen)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Fachinformation zu Latanoprost, Arzneimittelwechselwirkungen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (Fachinformation zu Adenosin, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Fachinformation zu Avanafil, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Celecoxib, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

• Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (Fachinformation zu Dexmedetomidin, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Diclofenac, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Diflunisal, Warnhinweise)

In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Etodolac, Warnhinweise)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Fenoprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Flurbiprofen, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n=23) and digoxin (n=30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Hydrocodon und Ibuprofen, Warnhinweise)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Ibuprofen und Famotidin, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Indometacin, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Fachinformation zu Ketoprofen, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Mefenaminsäure, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Meloxicam, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (Fachinformation zu Methylergometrin, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Nabumeton, Warnhinweise)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Naproxen und Esomeprazol, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Oxaprozin, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Salsalat, Warnhinweise)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (Fachinformation zu Sildenafil, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. (Fachinformation zu Sulindac, Warnhinweise)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Fachinformation zu Tadalafil, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Tolmetin, Warnhinweise)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Fachinformation zu Vardenafil, Warnhinweise und Vorsichtsmaßnahmen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (Fachinformation zu Adrenalin, Arzneimittelwechselwirkungen)

Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators. (Fachinformation zu Alfuzosin, Warnhinweise und Vorsichtsmaßnahmen)

Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential. (Fachinformation zu Carboprost, Warnhinweise)

Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (Fachinformation zu Dutasterid und Tamsulosin, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (Fachinformation zu Methohexital, Warnhinweise)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (Fachinformation zu Silodosin, Warnhinweise und Vorsichtsmaßnahmen)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (Fachinformation zu Tamsulosin, Warnhinweise und Vorsichtsmaßnahmen)